GH Research
Develops mebufotenin therapies and delivery systems for treatment-resistant depression.
$28.16
After-hours close+0.29 (+1.04%)
At close$27.87(−2.72%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.27 | — | — |
| Aug 2026 | −$0.29 | −$0.23 | +19.6% |
| May 2026 | −$0.27 | −$0.31 | −14.8% |
| Mar 2026 | −$0.29 | −$0.23 | +20.7% |
| Nov 2025 | −$0.23 | −$0.23 | 0.0% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Sep 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.27 | — | — | — | — | — |
| Aug 6, 2026 | −$0.29 | −$0.23 | +19.6% | — | — | — |
| May 14, 2026 | −$0.27 | −$0.31 | −14.8% | — | — | — |
| Mar 5, 2026 | −$0.29 | −$0.23 | +20.7% | — | — | — |
| Nov 6, 2025 | −$0.23 | −$0.23 | 0.0% | — | — | — |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 8, 2025 | ||||||
| Feb 27, 2025 | ||||||
| Nov 14, 2024 | ||||||
| Sep 3, 2024 | ||||||
| May 3, 2024 | ||||||
| Feb 29, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 23, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 2, 2023 | ||||||
| Nov 10, 2022 | ||||||
| Aug 23, 2022 | ||||||
| May 18, 2022 | ||||||
| Mar 28, 2022 | ||||||
| Dec 6, 2021 | ||||||
| Sep 23, 2021 | ||||||
| Jun 28, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||